A Phase I/IIa Study of GKL-006 Injection in Patients With Advanced Pancreatic Cancer

by | Aug 20, 2026 | Clinical Trials | 0 comments

​ Conditions: Advanced Pancreatic Cancer; Ductal Adenocarcinoma of Pancreas

Interventions: Biological: GKL-006 injection; Drug: Nab-paclitaxel and Gemcitabine

Sponsors: Beijing Gene Key Life Technology Co., Ltd

Active, not recruiting Conditions: Advanced Pancreatic Cancer; Ductal Adenocarcinoma of Pancreas
Interventions: Biological: GKL-006 injection; Drug: Nab-paclitaxel and Gemcitabine
Sponsors: Beijing Gene Key Life Technology Co., Ltd
Active, not recruiting 

Submit a Comment

Your email address will not be published. Required fields are marked *